sprifermin

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
02420142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OBJECTIVE Fibroblast growth factor (FGF) 18 has been shown to increase cartilage volume when injected intra-articularly in animal… (More)
Is this relevant?
2017
2017
Sprifermin (recombinant human fibroblast growth factor 18) is in clinical development as a potential disease-modifying… (More)
  • figure 1
  • figure 4
Is this relevant?
Review
2016
Review
2016
Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2016
2016
BACKGROUND A recent publication on efficacy of Sprifermin for knee osteoarthritis (OA) using quantitatively MRI-defined central… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
OBJECTIVES To evaluate the safety of intra-articular sprifermin (primary), and to evaluate systemic exposure, biomarkers… (More)
Is this relevant?
2015
2015
OBJECTIVE To determine whether an anabolic drug (sprifermin) is capable of reducing cartilage loss wherever it occurs in a given… (More)
  • table 1
  • table 2
  • figure 1
Is this relevant?
2015
2015
Augmented microfracture techniques use growth factors, cells, and/or scaffolds to enhance the healing of microfracture-treated… (More)
Is this relevant?
2014
2014
OBJECTIVE To evaluate the efficacy and safety of intraarticular sprifermin (recombinant human fibroblast growth factor 18) in the… (More)
Is this relevant?
2014
2014
In the search for structure-modifying treatments for osteoarthritis (OA), could the answer lie not in preventing degradation of… (More)
Is this relevant?
2014
2014
Introduction Osteochondral autograft transplantation (OAT) is a common procedure for the treatment of focal articular defects… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?